Evidence map›Paper›PMID 41764184›Full record

ArticleCell death & disease2026

Evaluation of non-canonical p53 functions in DNA replication and recombination for variant classification.

Rebecca Jansche, Benedikt Heitmeir, Ulrike Faust, Helmut Pospiech, Christian Sutter, Christian Albig, Finja Hennig, Wolfgang Janni, Rita Schmutzler, Jan Hauke and 2 more

Abstract read
In one paragraph

Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rebecca JanscheDepartment of Obstetrics and Gynecology, Ulm University, Ulm, Germany.
Benedikt HeitmeirDepartment of Obstetrics and Gynecology, Ulm University, Ulm, Germany.
Ulrike FaustInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany.
Helmut PospiechDepartment of Obstetrics and Gynecology, Center for Integrated Oncology (CIO), University Hospital and Medical Faculty of Heinrich Heine University, Düsseldorf, Germany.ORCID http://orcid.org/0000-0002-5255-0747
Christian SutterInstitute of Human Genetics, Department of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany.
Christian AlbigCenter for Hereditary Breast and Ovarian Cancer, Department of Obstetrics and Gynecology, LMU University Hospital, Munich, Germany.ORCID http://orcid.org/0000-0002-8320-5081
Finja HennigDepartment of Human Genetics, Hannover Medical School, Hannover, Germany.ORCID http://orcid.org/0000-0003-1717-9820
Wolfgang JanniDepartment of Obstetrics and Gynecology, Ulm University, Ulm, Germany.
Rita SchmutzlerCenter for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
Jan HaukeCenter for Hereditary Breast and Ovarian Cancer, Center for Integrated Oncology (CIO), Medical Faculty, University Hospital Cologne, Cologne, Germany.
Andreas C JoergerInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt am Main, Germany.ORCID http://orcid.org/0000-0002-1232-0138
Lisa WiesmüllerDepartment of Obstetrics and Gynecology, Ulm University, Ulm, Germany. lisa.wiesmueller@uni-ulm.de.ORCID http://orcid.org/0000-0002-2397-5041

Funding

Deutsche Krebshilfe (German Cancer Aid) Priority Program 'Translational Oncology', project HerediVar, 70114178Deutsche Krebshilfe (German Cancer Aid) Priority Program 'Translational Oncology', project HerediVar´, 70114178Deutsche Krebshilfe (German Cancer Aid) `TACTIC´, project number 70115201
6 · The paper itself

Abstract

Pathogenic germline TP53 variants predispose to diverse Li-Fraumeni syndrome (LFS) phenotypes and a broad cancer spectrum, whereby carriers of hypomorphic variants cluster in a cohort with attenuated disease onset and an overrepresentation of breast cancer (BC). Recently, functional assays have gained importance among the criteria used to predict the pathogenicity of hereditary breast and ovarian cancer (HBOC) risk-gene variants. Experimental assays scoring p53 functions in transcription and growth control have contributed to variant classification, yet a significant fraction of TP53 variants remain of unknown significance (VUS). To understand whether non-canonical functions of p53 in the fidelity control of DNA replication may aid variant classification, we subjected 23 TP53 VUS and 20 control variants identified in the German Consortium for HBOC (GC-HBOC) to assays that monitor nascent DNA synthesis and recombination-mediated bypass of replication barriers. Our results reveal a clear functional separation between benign (B)/likely benign (LB) and pathogenic (P)/likely pathogenic (LP) variants in recombination measurements, with B/LB variants associated with high recombination frequencies and P/LP variants with low recombination frequencies. Importantly, 8/23 VUS exhibited activities within the B/LB or P/LP ranges and therefore emerge as candidates for revised classification. Variant-specific recombination activities showed significant correlations with functional scores from four earlier studies systematically analyzing canonical p53 functions. Differently, in DNA fiber spreading assays B/LB and P/LP variants showed a more heterogeneous pattern and thus did not consistently recapitulate replication slow-down and acceleration observed in the presence and absence of p53, respectively. Structural modeling of separation-of-function (SOF) variants in transcription and recombination indicates varying effects on protein stability and the conformation of surface-exposed regions, affecting for example, the flexibility of Loop 1 (L1). Intriguingly, individual SOF variants suggest that loss-of-function (LOF) in recombination may drive BC, underscoring the predictive power of this assay for low-penetrance TP53 variants.

Indexed as

DNA ReplicationRecombination, GeneticTumor Suppressor Protein p53Breast NeoplasmsFemaleHumansLi-Fraumeni SyndromeTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID41764184
PMCPMC13031496

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.